Join the Semaglutide group to help and get support from people like you.
Semaglutide News
Semaglutide Not Linked to Increased Risk of Eye Disorders, Diabetic Retinopathy
MONDAY, Aug. 18, 2025 – For adults with diabetes, semaglutide treatment is not associated with increased risk of eye disorders or diabetic retinopathy, according to a review published online Aug. 14...
Wegovy Approved in the US for the Treatment of MASH
Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy (semaglutide 2.4 mg) based on a supp...
26.5 Percent of Adults With Diabetes Used GLP-1 RA Injectables in 2024
THURSDAY, Aug. 14, 2025 – In 2024, 26.5 percent of adults with diagnosed diabetes used glucagon-like peptide 1 receptor agonist (GLP-1 RA) injectables, according to an August data brief published by...
GLP-1 Receptor Agonists May Reduce Complications of Diabetic Retinopathy
TUESDAY, Aug. 12, 2025 – For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a slightly increased risk for incident diabetic...
Study IDs Barriers to GLP-1 Receptor Agonist Use in Adolescents, Young Adults
THURSDAY, Aug. 7, 2025 – A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured, and many young adults do not have...
GLP-1 Receptor Agonist Use Linked to Nonarteritic Anterior Ischemic Optic Neuropathy
TUESDAY, Aug. 5, 2025 – For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with nonarteritic anterior ischemic optic neuropathy (NAION),...
Rebound Weight Gain Common After Discontinuing Antiobesity Medications
FRIDAY, July 25, 2025 – Antiobesity medications (AOMs) yield weight loss during use, followed by weight regain after discontinuation of treatment, according to a review published online July 21 in...
GLP-1 Receptor Agonist Use Linked to Lower Mortality in Seniors With Cancer, T2D
THURSDAY, July 24, 2025 – For older patients with cancer and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with lower all-cause mortality than...
GLP-1 Receptor Agonists Tied to Decrease in T2DM-Related Dementia Risk
WEDNESDAY, July 23, 2025 – Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with metformin, according...
Risk for Dementia, Ischemic Stroke, Mortality Lower With GLP-1 Receptor Agonists in T2D, Obesity
TUESDAY, July 22, 2025 – For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause...
Dementia Risk Does Not Differ With GLP-1 RAs, DPP4is for Seniors With T2DM
MONDAY, July 21, 2025 – For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using glucagon-like peptide 1 receptor agonists (GLP-1...
GLP-1 Receptor Agonists May Improve Outcomes in Idiopathic Intracranial Hypertension
MONDAY, July 21, 2025 – For patients with idiopathic intracranial hypertension (IIH), glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is associated with improved clinical outcomes...
ENDO: Guidelines Developed for Pregnancy Care in Preexisting Diabetes
FRIDAY, July 18, 2025 – In a joint clinical practice guideline issued by the Endocrine Society and European Society of Endocrinology, recommendations are presented for pregnancy care in individuals...
Diabetic Women Should Be Asked About Desire For Kids At Every Doctor's Visit, Guidelines Say
FRIDAY, July 18, 2025 — Doctors should ask diabetic women at every visit about their intention to have a child, to make sure they get the appropriate care prior to conception, new guidelines say. T...
GLP-1 Receptor Agonist Use in T2D Tied to Increased Risk for GERD, GERD Complications
THURSDAY, July 17, 2025 – For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an increased risk for gastroesophageal reflux disease (GERD)...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Chronic Kidney Disease, Cardiovascular Risk Reduction, Diabetes, Type 2, Nonalcoholic Fatty Liver Disease